Exonhit Announces Successful Completion of the Second Phase of EHT Dx14 Clinical Validation
EHT Dx14 determinates the exact nature of breast tumors in more than 90% of cases
21-Jul-2011 -
Following the first data in benign and malignant fine-needle aspiration (FNA) samples, Exonhit announced successful completion of the second phase of the validation study of EHT Dx14, a new transcriptomic signature allowing to differentiate, at molecular level, benign breast tumors from malignant ...
breast cancer
ExonHit Therapeutics